3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Breast
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Conditions
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
264
Carboplatin
246
Cisplatin
153
Bevacizumab
104
Gemcitabine
78
Topotecan
77
liposomal doxorubicin
67
pembrolizumab
60
Docetaxel
56
Cyclophosphamide
50
Taxes
48
Radiotherapy
44
olaparib
43
Surveys and Questionnaires
43
Doxorubicin
43
Filgrastim
42
Brachytherapy
37
Drug Therapy
31
niraparib
28
Blood Specimen Collection
28
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
26
human papillomavirus vaccine, L1 type 16, 18
24
Peripheral Blood Stem Cell Transplantation
23
atezolizumab
22
Oxaliplatin
22
Pemetrexed
21
Nivolumab
21
Hyperthermic Intraperitoneal Chemotherapy
21
Etoposide
21
Immunoglobulin G
20
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glucose
×
Gynecologic
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts